Department of Head and Neck Oncology and Surgery, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
Department of Oral and Maxillofacial Surgery, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Cancer Med. 2021 Jan;10(1):424-434. doi: 10.1002/cam4.3598. Epub 2020 Nov 28.
Salivary and mammary gland tumors show morphological similarities and share various characteristics, including frequent overexpression of hormone receptors and female preponderance. Although this may suggest a common etiology, it remains unclear whether patients with a salivary gland tumor carry an increased risk of breast cancer (BC). Our purpose was to determine the risk of BC in women diagnosed with salivary gland carcinoma (SGC) or pleomorphic adenoma (SGPA). BC incidence (invasive and in situ) was assessed in two nationwide cohorts: one comprising 1567 women diagnosed with SGC and one with 2083 women with SGPA. BC incidence was compared with general population rates using standardized incidence ratio (SIR). BC risk was assessed according to age at SGC/SGPA diagnosis, follow-up time and (for SGC patients) histological subtype. The mean follow-up was 7.0 years after SGC and 9.9 after SGPA diagnosis. During follow-up, 52 patients with SGC and 74 patients with SGPA developed BC. The median time to BC was 6 years after SGC and 7 after SGPA. The cumulative risk at 10 years of follow-up was 3.1% after SGC and 3.5% after SGPA (95% Confidence Interval (95%CI) 2.1%-4.7% and 2.6%-4.6%, respectively). BC incidence was 1.59 times (95%CI 1.19-2.09) higher in the SGC-cohort than expected based on incidence rates in the general population. SGPA-patients showed a 1.48 times (95%CI 1.16-1.86) higher incidence. Women with SGC or SGPA have a slightly increased risk of BC. The magnitude of risk justifies raising awareness, but is no reason for BC screening.
唾液腺和乳腺肿瘤具有形态学相似性，并具有多种共同特征，包括激素受体的频繁过表达和女性发病优势。尽管这可能表明有共同的病因，但尚不清楚患有唾液腺癌（SGC）的患者是否有更高的乳腺癌（BC）风险。我们的目的是确定诊断为唾液腺癌（SGC）或多形性腺瘤（SGPA）的女性患乳腺癌的风险。在两个全国性队列中评估了 BC 的发病率（浸润性和原位性）：一个队列包含 1567 名诊断为 SGC 的女性，另一个队列包含 2083 名诊断为 SGPA 的女性。使用标准化发病率比（SIR）比较 BC 发病率与普通人群的比率。根据 SGC/SGPA 诊断时的年龄、随访时间以及（对于 SGC 患者）组织学亚型评估 BC 风险。SGC 诊断后的平均随访时间为 7.0 年，SGPA 诊断后的平均随访时间为 9.9 年。在随访期间，52 名 SGC 患者和 74 名 SGPA 患者发生了 BC。SGC 诊断后中位时间为 6 年，SGPA 诊断后中位时间为 7 年。10 年随访时的累积风险分别为 SGC 后 3.1%和 SGPA 后 3.5%（95%置信区间（95%CI）分别为 2.1%-4.7%和 2.6%-4.6%）。与普通人群的发病率相比，SGC 队列中 BC 的发病率高 1.59 倍（95%CI 1.19-2.09）。SGPA 患者的发病率高 1.48 倍（95%CI 1.16-1.86）。患有 SGC 或 SGPA 的女性患 BC 的风险略有增加。风险的幅度值得提高认识，但不是进行 BC 筛查的理由。
